We therefore compared conventional breast cancer blood biomarkers (CA15-3 and alkaline phosphatase (AP)) with CTC counts and simple measurement of total cfDNA levels, rather than ctDNA profiles to assess the best predictor of response to treatment and prognosis in 194 patients with metastatic breast cancer. This evidence concerns the gene DHCR7-DT and breast carcinoma.